NDMC101 exhibits immunomodulatory effects and inhibits dipeptidyl peptidase-IV activity in human T cells. NDMC101 is also an osteoclastogenesis inhibitor for experimental arthritis. Its efficacy is associated with the inhibition of such transcription factors as NF-κB and NFATc1 as well as multiple protein kinases, including p38, ERK, and JNK.

KEYWORDS: NDMC101 | supplier | DPP-4 inhibitor | HS-Cm | NDMC 101 | NDMC-101 | CAS [1308631-40-4] | Non Selective (Proline Peptide Bonds) | DPP4 | Inhibitor | Enzymes | Arthritis | Rheumatoid arthritis | Atherosclerosis